Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes. The Company has developed a series of product candidates that are designed specifically to trap and allow for the degradation of free aldehydes. The Company's most advanced product candidate is an eye drop formulation of NS2, which is under development for the treatment of Sjogren-Larsson Syndrome (SLS). The Company has completed a double-masked, placebo-controlled, Phase I clinical testing of 0.25% and 0.5% NS2 administered as an eye drop for safety and tolerability in approximately 48 healthy volunteers. Data from the Phase I study demonstrated that NS2 was well tolerated in all subjects throughout the duration of the study.
Company Growth (employees)
Lexington, US
Size (employees)
6 (est)
Aldeyra Therapeutics was founded in 2004 and is headquartered in Lexington, US

Aldeyra Therapeutics Office Locations

Aldeyra Therapeutics has office in Lexington
Lexington, US

Aldeyra Therapeutics Metrics

Aldeyra Therapeutics Summary

Market capitalization

$32.8 m

Closing share price

Aldeyra Therapeutics's current market capitalization is $32.8 m.

Aldeyra Therapeutics Market Value History

Aldeyra Therapeutics Online Presence

Aldeyra Therapeutics Company Life

You may also be interested in